Corrigendum to 'Early Immunosuppression as CRS Prophylaxis in Outpatient Haploidentical Transplants: A Randomized Phase II Study' [Transplantation and Cellular Therapy volume 32 (2026) 11.e-11.e4/Article Number] [0.03%]
Perla R Colunga-Pedraza,Héctor A Vaquera-Alfaro,Andrés Gómez-De León et al.
Perla R Colunga-Pedraza et al.
Neurocognitive Dysfunction in Patients Treated with Chimeric Antigen Receptor (CAR) T-cell Therapy Worse for Patients with Neurotoxicity [0.03%]
Aasha I Hoogland,Heather S L Jim
Aasha I Hoogland
Stijn E Verleden,Geert M Verleden
Stijn E Verleden
Adela Rambi Guanco Cardones
Adela Rambi Guanco Cardones
Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma [0.03%]
Silvia Escribano Serrat,Andrew Ip,Jaime Sanz et al.
Silvia Escribano Serrat et al.
The approval of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in the second-line (2L) setting for large B-cell lymphoma (LBCL) has reshaped treatment sequencing and the population at risk for post-CAR-T relapse; however, management ...
Neurotoxicity in older patients with relapsed or refractory large B-cell lymphoma treated with CAR T-cell therapy: A multicenter study [0.03%]
Aung M Tun,Romil Patel,Frederique St-Pierre et al.
Aung M Tun et al.
Purpose: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a standard treatment option in relapsed or refractory (RR) large B-cell lymphoma (LBCL), including older patients. However, immune effector cell-assoc...
Corrigendum to "Umbilical cord blood reduced relapse but increased non-relapse mortality compared to matched unrelated donor transplantation in pediatric AML with active disease: A CIBMTR 2008-2017 analysis of donor source and residual disease" Transplantation and Cellular Therapy (Volume 31, Issue 4, April 2025, Pages 261.e1-261.e15) [0.03%]
Takuto Takahashi,Franziska Wachter,Francesca Alvarez Calderon et al.
Takuto Takahashi et al.
Corrigendum to "Effects of total body irradiation on hematopoietic cell transplantation outcomes in pediatric acute myeloid leukemia with prior central nervous system involvement" Journal title: Transplantation and Cellular Therapy (Volume 30, Issue 8, August 2024, Pages 812.e1-812.e11) [0.03%]
Takuto Takahashi,Alexander J Lake,Franziska Wachter et al.
Takuto Takahashi et al.
Value‑Based Contracting for Cell and Gene Therapies: A Scoping Review of Payer-Manufacturer Agreements and Treatment‑Center Considerations in USA [0.03%]
Pranav M Patel,Amy Heck Sheehan,Cynthia Wan et al.
Pranav M Patel et al.
Background: Cell and gene therapies (CGTs) offer the potential for durable or curative outcomes, but come with high upfront costs and uncertainty about long-term safety and effectiveness. To address these challenges, manu...
Prognostic Impact of BK Polyomavirus Viremia Detected by Multiplex Plasma PCR Following Allogeneic Hematopoietic Cell Transplantation [0.03%]
Ryo Hasunuma,Hiroaki Shimizu,Daichi Sadato et al.
Ryo Hasunuma et al.
After allogeneic hematopoietic cell transplantation (allo-HCT), the reactivation of opportunistic viruses, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK human polyomavirus (BKPyV), adenovirus (ADV), and human herpesvirus-6 (HH...